Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
- Conditions
- Gastrointestinal CarcinomaPancreatic CancerHepatocellular CancerCholangiocarcinomaDuodenal CancerColorectal CancerSmall Bowel CancerMetastatic Cancers
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT06690281
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
- Conditions
- Non-Small Cell Lung CancerGastrointestinal CancerOvarian CancerMetastatic Solid CancersColorectal CancerBreast CancerGenitourinary Cancer
- Interventions
- Drug: AldesleukinDrug: FludarabineDrug: CyclophosphamideBiological: KRAS TCR-Transduced PBLBiological: GRT-C903/GRT-R904
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 210
- Registration Number
- NCT06253520
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: AldesleukinBiological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T LymphocytesProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: MammogramProcedure: Multigated Acquisition ScanProcedure: Ultrasound Imaging
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 20
- Registration Number
- NCT05989828
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
- Conditions
- Recurrent NeuroblastomaRegional NeuroblastomaStage 4S NeuroblastomaStage 4 NeuroblastomaLocalized Resectable NeuroblastomaLocalized Unresectable Neuroblastoma
- Interventions
- Drug: IsotretinoinBiological: AldesleukinOther: Laboratory Biomarker AnalysisBiological: DinutuximabOther: Pharmacological StudyOther: Quality-of-Life AssessmentBiological: Sargramostim
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1449
- Registration Number
- NCT00026312
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.